Reference / reference entry — not sold here, and — being an antibody — not something the gray market can even make. It's here because it sits at the hottest theme in obesity right now: preserving muscle during GLP-1 weight loss. And it has one of the best redemption stories in the field. No dosing p
Bimagrumab is a monoclonal antibody that blocks the activin type II receptors, producing a unique effect — fat loss with simultaneous muscle gain. Originally a failed muscle-wasting drug, it was revived for obesity (Versanis → Lilly's ~$1.9B buyout) and is now the lead candidate for the field's hottest goal: preserving muscle during GLP-1 weight loss. Phase 2 data (alone and with semaglutide) are genuinely promising, but it is investigational, not approved, still carries the old "builds muscle without always improving function" caveat, and — as an antibody — exists only as a pharma asset, not a sellable or gray-market product.
- Everywhere — investigational, not approved. Multiple Phase 2/2b obesity trials ongoing (semaglutide combo positive; tirzepatide combos mixed; readouts 2026). - Gray market: effectively none — a monoclonal antibody requires complex biologic manufacturing and cannot be casually synthesised or sold the way peptides are. It's a pure pharma-pipeline asset (and, in this register, a notable marker of i
An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.
A credentialed reviewer (PharmD / PhD / MD) will be named before this entry is finalised. Until then, treat it as a working draft. Last updated July 2026 (fast-moving — re-check the 2026 tirzepatide-combination readouts).
Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.
A neutral reference and a lawful-lane shop. Registered in Spain. Information for those who seek it — never promotion.
This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia SL — Registered in Spain.